Trial Profile
A Phase II Study of Pre-Operative Docetaxel for Progressive Localized Castration Resistant Prostate Cancer.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Prednisone
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- 24 Sep 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 13 Jul 2010 Planned initiation date changed from 1 Jun 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.
- 13 Jul 2010 Planned end date changed from 1 Dec 2010 to 1 Jan 2012 as reported by ClinicalTrials.gov.